When was Boston Translational LLC's most recent SEC filing?

Boston Translational LLC's most recent Form D filing was on 2018-04-16.

How many investors does Boston Translational LLC have?

The most recent Form D filing lists 4 investor(s).

What type of securities does Boston Translational LLC offer?

Boston Translational LLC's SEC Form D filings indicate equity, debt offerings.

Boston Translational LLC

CIK: 0001717227·Biotechnology·Allston, MA·Limited Liability Company·Founded 2017

Reported Sold

N/A

Total Filings

Identified Offerings

Last Filed

Apr 16, 2018

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately. 1 unlinked amendment excluded.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Apr 16, 2018Form D/A — Amendment

Reported sold: $1,825,000 · Target: $4,000,000

No verified predecessor available.

Rule 506(b)·4 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

No Revenues

Reported commissions across identified offerings

N/A

Amendment Rate

100%

Latest reported sold across 0 identified offerings

N/A

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

1 unlinked amendment excluded.

Key People

Paul Holzer

Related Person

Appears on 1 filing

Krysta Moulton

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Apr 16, 2018	Amendment	$4,000,000	$1,825,000	4

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Axelyf, Inc.

Biotechnology

Offering target: $2,700,000

Filed Oct 13, 2026